Description
Product Description
Dalpiciclib Isethionate (CAS 1980822-14-7) is a potent and selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. CDK4/6 are crucial regulators of the G1-to-S phase transition in the cell cycle. By inhibiting CDK4/6, Dalpiciclib Isethionate induces cell cycle arrest in sensitive cancer cells, making it a valuable tool for research in oncology, cell biology, and drug discovery.
The high-purity powder ensures reproducibility in vitro, including studies on breast cancer, melanoma, and hematological malignancies. It has been extensively used in combination with other chemotherapeutics or targeted agents to explore synergistic effects and mechanisms of resistance. Researchers can integrate Dalpiciclib Isethionate into high-throughput screening assays, tumor organoid cultures, and preclinical pharmacology studies.
Dalpiciclib Isethionate offers advantages including high chemical stability, solubility in common laboratory solvents, and compatibility with cell culture and molecular assays. Its rigorous quality control ensures minimal impurities, consistent batch-to-batch performance, and reliable results across experimental models.
The compound’s mechanism of action enables detailed study of CDK4/6-mediated phosphorylation of retinoblastoma (Rb) protein, E2F transcription factor activation, and downstream cell proliferation pathways. In combination with genetic knockdowns or overexpression studies, Dalpiciclib Isethionate facilitates precise mapping of cell cycle checkpoints and tumor suppressor pathways.

Product Specifications
| Parameter | Details |
|---|---|
| Chemical Name / Synonyms | Dalpiciclib Isethionate, SHR6390, CDK4/6 inhibitor |
| CAS Number | 1980822-14-7 |
| Molecular Formula | C₂₈H₂₉N₅O₇S |
| Molecular Weight | 567.6 g/mol |
| Purity | ≥99% (HPLC, LC-MS verified) |
| Appearance | White to off-white crystalline powder |
| Dosage Form | Powder |
| Solubility | Soluble in DMSO, ethanol, aqueous buffers; stable under standard laboratory conditions |
| Concentration | Customizable, typically 1–50 mM stock solutions in DMSO for in vitro assays |
| Storage Temperature | 2–8°C; avoid freeze-thaw cycles and light exposure |
| Stability | Maintains structural integrity and bioactivity for ≥12 months under recommended storage |
| Analytical Methods | HPLC, LC-MS, NMR, UV spectroscopy, functional kinase assays, endotoxin testing |
| Mechanistic Target | CDK4 and CDK6 |
| Structural Category | Small-molecule kinase inhibitor |
| Applications | Cell cycle studies, tumor proliferation assays, preclinical drug discovery, combination therapy research, high-throughput screening |
| Batch Consistency | GMP-compliant, verified via analytical and functional assays |
| Regulatory Notes | Research-use only; not for human or veterinary use |
| Origin | Synthesized under GMP-compliant laboratory conditions |
| Additional Data | Certificate of Analysis (CoA), analytical reports, endotoxin ≤0.1 EU/mg, stability and solubility data |
Mechanism of Action
Dalpiciclib Isethionate selectively binds to CDK4 and CDK6, inhibiting their kinase activity. This prevents phosphorylation of the retinoblastoma protein (Rb), maintaining Rb in its active form, which sequesters E2F transcription factors and halts progression from G1 to S phase. Inhibition of CDK4/6 signaling results in cell cycle arrest, reduced proliferation, and increased sensitivity of tumor cells to other therapeutic agents.
It has been validated in multiple cancer cell lines, including ER+/HER2− breast cancer, demonstrating dose-dependent G1-phase arrest. Mechanistic studies also show that Dalpiciclib Isethionate affects downstream targets such as cyclin D1 and p21/p27 regulators, impacting apoptosis, senescence, and DNA damage responses. Its small-molecule nature allows easy combination with other inhibitors or chemotherapeutics to study synergistic effects and overcome drug resistance mechanisms.
Dalpiciclib Isethionate is also used to explore pharmacodynamic biomarkers and molecular pathways in preclinical animal models. The compound’s consistent activity, high purity, and solubility facilitate integration into cell-based assays, organoid cultures, and high-throughput screening systems.

Side Effects
In laboratory settings, Dalpiciclib Isethionate can cause dose-dependent cytotoxicity or growth arrest in sensitive cell lines. High concentrations may induce off-target effects, including mild inhibition of other kinases. Standard precautions include handling with gloves and protective equipment, avoiding inhalation or ingestion, and storing under recommended conditions.
Researchers are advised to titrate doses to achieve desired cell cycle inhibition without affecting overall cell viability unnecessarily. The compound’s stability under recommended storage ensures reproducible bioactivity across multiple experiments, supporting reliable preclinical and translational studies.
Keywords
Dalpiciclib Isethionate, CAS 1980822-14-7, CDK4/6 inhibitor, cell cycle inhibitor, small-molecule kinase inhibitor, high-purity chemical, bulk supply, GMP OEM, research reagent, tumor proliferation, preclinical pharmacology, laboratory assay, combination therapy research, oncology research, drug discovery, China chemical manufacturer, factory small-molecule supplier
Shipping Guarantee
Dalpiciclib Isethionate powder is shipped under controlled conditions with cold packs if needed, ensuring stability during transport. Packaging is leak-proof and secure, with global tracking and insurance for reliable delivery to research laboratories worldwide.
Trade Assurance
Each batch is verified for ≥99% purity, with CoA and analytical reports provided. GMP-compliant production ensures consistent batch quality. Returns and exchanges are supported in case of QC-related issues.
Payment Support
Payments accepted via PayPal, T/T, bank transfer, USDT, Bitcoin, Ethereum, and credit card. Encrypted verification ensures secure transactions for bulk and OEM orders globally.
Disclaimer
Dalpiciclib Isethionate is intended for laboratory research only. It is not for human or veterinary use. Follow standard biosafety procedures during handling.
References
PubChem: https://pubchem.ncbi.nlm.nih.gov/
ChEMBL: https://www.ebi.ac.uk/chembl/
DrugBank: https://go.drugbank.com/
PubMed: https://pubmed.ncbi.nlm.nih.gov/
IUPHAR/BPS: https://www.guidetopharmacology.org/


Reviews
There are no reviews yet.